Lansen Pharmaceutical Holdings Limited provided earnings guidance for the twelve months ended 31 December 2022. For the period, the group expected to record a net profit attributable to equity owners of approximately USD 8.1 million, representing an increase of approximately USD 7.2 million (approximately 798% increase) compared to that of last year of approximately USD 0.9 million.
Lansen Pharmaceutical Holdings Limited
Equities
503
KYG5380M1033
Pharmaceuticals
1st Jan change | Capi. | |
---|---|---|
+60.25% | 841B | |
+38.56% | 625B | |
-4.49% | 360B | |
+18.30% | 327B | |
+9.64% | 300B | |
+14.15% | 242B | |
+3.11% | 228B | |
+16.98% | 227B | |
+12.87% | 174B |